Prudential Financial Inc. lessened its holdings in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 95.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,960 shares of the medical research company’s stock after selling 160,160 shares during the period. Prudential Financial Inc.’s holdings in PRA Health Sciences were worth $530,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 160 shares during the last quarter. Carroll Financial Associates Inc. lifted its stake in shares of PRA Health Sciences by 127.4% in the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 790 shares during the last quarter. Trustmark National Bank Trust Department bought a new position in PRA Health Sciences in the 2nd quarter worth $225,000. Aperio Group LLC bought a new position in PRA Health Sciences in the 2nd quarter worth $233,000. Finally, Ameritas Investment Partners Inc. raised its holdings in PRA Health Sciences by 62.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,404 shares of the medical research company’s stock worth $255,000 after acquiring an additional 1,315 shares during the period. 98.49% of the stock is owned by institutional investors and hedge funds.

PRA Health Sciences, Inc. (NASDAQ PRAH) opened at $82.71 on Monday. PRA Health Sciences, Inc. has a twelve month low of $53.47 and a twelve month high of $84.38. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. The stock has a market cap of $5,241.31, a PE ratio of 30.41, a PEG ratio of 1.43 and a beta of 0.40.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The company had revenue of $494.55 million for the quarter, compared to the consensus estimate of $477.89 million. During the same quarter in the previous year, the firm posted $0.64 EPS. The business’s revenue was up 23.7% compared to the same quarter last year. equities research analysts forecast that PRA Health Sciences, Inc. will post 3.2 earnings per share for the current year.

In other news, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.

PRAH has been the topic of several recent analyst reports. Jefferies Group reiterated a “buy” rating and issued a $95.00 target price on shares of PRA Health Sciences in a report on Thursday, October 26th. Zacks Investment Research downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. KeyCorp reiterated a “buy” rating and issued a $93.00 target price (up previously from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. Robert W. Baird set a $94.00 target price on shares of PRA Health Sciences and gave the stock a “buy” rating in a report on Friday, December 1st. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $90.00 target price (up previously from $84.00) on shares of PRA Health Sciences in a report on Monday, October 16th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $89.09.

COPYRIGHT VIOLATION NOTICE: “Prudential Financial Inc. Has $530,000 Position in PRA Health Sciences, Inc. (PRAH)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/prudential-financial-inc-has-530000-position-in-pra-health-sciences-inc-prah/1757182.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.